Comparison
Dulaglutide vs. Epitalon
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Research other
CAS no.
923950-08-7
307297-39-8
Molecular weight
59670 g/mol
390.35 g/mol
Half-life
110 h
0.3 h
Sequence
GLP-1(7-37)-Variante kovalent verbunden mit modifiziertem humanen IgG4-FcAla-Glu-Asp-GlyMechanism of action
Dulaglutide
Dulaglutide consists of two modified GLP-1(7-37) sequences covalently linked to a human IgG4-Fc. The Fc fusion increases molecular weight substantially (~60 kDa), reduces renal filtration and extends the half-life to several days. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon, delays gastric emptying and modulates central satiety signalling.
Epitalon
Postulated mechanisms include modulation of gene expression in pinealocytes, telomerase activation (observed in cell culture studies) and influence on melatonin synthesis. A defined primary receptor is not established; the mechanistic basis rests on in-vitro and animal data from the Khavinson group.
Evidence base
Highest evidence
Human RCT
Human trial
Studies
5
4
of which in humans
5
1
Effects recorded
3
4
Open conflicts
0
1
Documented adverse events
2
1